Detection and monitoring of serum p53 antibodies in patients with colorectal cancer

Gut

Volumn 40, Issue 3, 1997, Pages 356-361

  Hammel, P ^a,g   Boissier, B ^b   Chaumette, M T ^c   Piedbois, P ^d   Rotman, N ^e   Kouyoumdjian, J C ^b   Lubin, R ^f   Delchier, J C ^a   Soussi, T ^f  

^a Serv d'Hepatologie Gastroenterol   (France)

^b Laboratoire de Biochimie

^c Lab d'Anat Pathologique C   (France)

^d Service de Cancérologie

^e HENRI MONDOR HOSPITAL   (France)

^f INSERM   (France)

^g BEAUJON HOSPITAL   (France)

Author keywords

carbohydrate antigen 19 9; carcinoembryonic antigen; colorectal cancer; p53 antibodies; p53 gene

Indexed keywords

ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PATIENT MONITORING; PRIORITY JOURNAL;

EID: 0030958208     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.40.3.356     Document Type: Article

References (28)

1. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer; a review. Int J Cancer 1994; 57: 1-9.
2. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. Science 1991; 253: 49-53.
3. Bourdon JC, D'Errico A, Paterlini P, Grigioni W, May E, Debuire B. p53 protein accumualtion in european hepatocellular carcinoma is not always dependent on p53 gene mutation. Gastroenterology 1995; 108: 1176-82.
4. Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B, Thomas G. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 1992; 66: 758-64.
5. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994; 106: 42-8.
6. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch H, et al. Accumulation of p53 tumour suppressor gene protein - an independant marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84: 845-55.
7. Starzynska T, Bromley M, Ghosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992; 66: 558-62.
8. Porter PL, Gown AM, Kramp SG, Coltrera MD. Widespread p53 overexpression in human malignant tumours. Am J Pathol 1992; 140: 145-53.
9. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982; 30: 403-8.
10. Caron de Fromentel C, May-Levin F, Mouriesse H, Lemerle J, Chandrasekaran K, May P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 1987; 39: 185-9.
11. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 1992; 89: 3439-42.
12. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992; 52: 6380-4.
13. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992; 52: 4168-74.
14. Labrècque S, Naor N, Thomson D, Matlashewski G. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 1993; 53: 3468-71.
15. Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumour suppressor gene protein in various cancers. Int J Cancer 1994; 58: 480-7.
16. Lubin R, Zalcman G, Bouchet L, Trédanel J, Legros Y, Cazals D, et al. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995; 1: 701-2.
17. Preudhomme C, Lubin R, Lepelley P, Vanrumbeke M, Fenaux P. Detection of serum anti-p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 1994; 8: 1589-91.
18. Wild CP, Ridanpää M, Anttila S, Lubin R, Soussi T, Husgafvel-Fursiainen K, Vanino H. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutations in the tumour tissue. Int J Cancer 1995; 64: 176-81.
19. Legros Y, Lafon C, Soussi T. Linear antigenic sites denned by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. Oncogene 1994; 9: 2071-6.
20. Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Tredaniel J, Hirsch A, et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 1993; 53: 5872-6.
21. Schlichtholz B, Trédaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 1994; 69: 809-16.
22. Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild CP, Soussi T. p53 antibodies in patients with various types of cancer: identification and characterization. Clin Cancer Res 1995; 1: 1463-9.
23. Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J, Soussi T. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 1995; 345: 621-2.
24. Schein PS. Gastrointestinal cancer: a global perspective. In: JD Ahlgren, JS Macdonald, eds. Gastrointestinal oncology. Philadelphia: JB Lippincott, 1992: 3-11.
25. Dukes CE. The classification of cancer of the rectum. J Pathol Bacteriol 1932; 35: 323-32.
26. Guinee Jr DG, Travis WD, Trivers GE, De Benedetti VMG, Cawley H, Welsh JA, et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies, and C-erb B-2 expression. Carcinogenesis 1995; 16: 993-1002.
27. Johnson KA, Wolley PV. The role of tumour markers in the management of gastrointestinal malignancies. In: JD Ahlgren, JS Macdonald, eds. Gastrointestinal oncology. Philadelphia: JB Lippincott, 1992: 63-65.
28. Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, Burmer GC. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994; 107: 369-78.